Cellebrite DI (NASDAQ:CLBT) Given New $25.00 Price Target at JPMorgan Chase & Co.

Cellebrite DI (NASDAQ:CLBT) had its price target decreased by research analysts at JPMorgan Chase & Co. from $29.00 to $25.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 26.68% from the stock’s current price.

CLBT has been the topic of a number of other reports. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Lake Street Capital increased their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI has a consensus rating of “Buy” and a consensus price target of $23.00.

Cellebrite DI Stock Performance

NASDAQ:CLBT traded down $0.11 during trading hours on Monday, reaching $19.73. The stock had a trading volume of 696,709 shares, compared to its average volume of 1,427,410. The stock has a market cap of $4.73 billion, a P/E ratio of -14.18, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The stock has a 50 day simple moving average of $18.92 and a 200 day simple moving average of $20.25. Cellebrite DI has a 12-month low of $10.25 and a 12-month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, equities analysts expect that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CLBT. Assetmark Inc. purchased a new stake in Cellebrite DI in the first quarter valued at approximately $33,000. Catalyst Capital Advisors LLC purchased a new stake in shares of Cellebrite DI during the 1st quarter valued at $51,000. Gen Wealth Partners Inc bought a new stake in shares of Cellebrite DI during the 4th quarter worth $85,000. NewEdge Advisors LLC grew its position in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after acquiring an additional 3,352 shares in the last quarter. Finally, R Squared Ltd purchased a new position in Cellebrite DI in the fourth quarter worth $100,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.